The Role of Adult Stem Cells in Angioplasty

The National Institute of Health has granted the Creighton School of Medicine $3.3 million dollars to study repairing damaged coronary arteries with adult stem cells. Such damage can occur when patients undergo coronary artery angioplasty and stenting.

A serious problem that occurs is the re-narrowing (restenosis) of coronary arteries after stent placement. Stents are used to help widen narrowed arteries. Restenosis can be reduced by using drug-eluding stents but they can also lead to deposits of blood platelets within the artery that destroy its lining. To counteract this effect, anti-platelet therapy is employed. However, upset stomach, diarhea and nausea are serious side effects that are caused by anti-platelet therapy.

Creighton researchers, Devendra Agrawal, Ph.D, Michael Del Core and William Hunter are the primary and co-investigators. Dr. Agrawal is a professor of biomedical sciences. Dr. Del Core is a cardiologist and Dr. Hunter is a pathologist.

Autologous mesenchymal stem cells will be delivered with a specialized gene into the coronary arteries of pigs. The goal of this study is to determine if adult stem cell + gene therapy is superior to drug eluting stents, which are today’s standard of care. Such a treatment could eliminate the need for stents altogether if successful.

Recent research has shown that angioplasty and stenting – commonly used to open narrowed coronary arteries – are not as effective as once thought.

The Archives of Internal Medicine published a study of 15,000 patients showing that angioplasty + stenting can cause more harm than good in certain patients. The study determined that 10% of patients had to be readmitted to a hospital within 30 days of stenting and that they were at a higher risk of death within 1 year than the other 90%.

Medistem and Licensee ERCell Receive Russian Regulatory Approval for the RECOVER-ERC Trial

The clinical trial, Non-Revascularizable IschEmic Cardiomyopathy treated with Retrograde COronary Sinus Venous DElivery of Cell TheRapy (RECOVER-ERC), is being led by Principle Investigator Dr. Leo Bockeria, Chairman of the Backulev Center http://www.bakulev.ru/en/about/director/.

The Backulev Center is Russia’s premier institute for cardiovascular surgery and cardiology. Every year the Backulev Center performs approximately 30,000 diagnostic and treatment procedures, which includes 7,000 open heart surgeries and more than 12,000 angioplasties.

The RECOVER-ERC trial will recruit 60 patients with congestive heart failure, and randomize the patients into 3 groups of 20 patients each. Group 1 will receive 50 million ERC, Group 2 will receive 100 million and Group 3 will receive 200 million. Each group will have 15 patients receiving cells and 5 patients receiving placebo. Efficacy endpoints include ECHO and MRI analysis, which will be conducted at 6 months after treatment.

“I joined Medistem and personally invested into the company because of its strong science and intellectual property position. It is this strong science that has allowed for such a rapid progression of the ERC product from discovery, to animal studies, and now to approval for initiation of efficacy finding studies,” said Dr. Vladimir Bogin, President and Chairman of Medistem, and a Yale-trained physician practicing in the USA. “As a medical doctor I see the suffering and lack of options for patients with CHF. I am proud that our team is able to offer hope.”

This is the second clinical trial that Medistem has been granted approvals for. In September 2011, the company received FDA clearance for beginning a 15 patient trial treating critical limb ischemia patients together with Dr. Michael Murphy at Indiana University.

“We are especially grateful to our Russian licensee ERCell LLC which has worked intensely with our CRO and the Backulev Center in laying down the groundwork for this approval,” said Vladimir Zaharchook, Vice President and Vice Chairman of Medistem. “To our knowledge, ERCell is the only company in Russia working on a stem cell product that can be reproducibly manufactured, frozen, and sold as a drug, not a procedure.”

“This approval is a key milestone for ERCell. Given that Russia has one of the highest incidences of heart failure per capita in the world, we are confident that we can make a difference in patients’ lives and position Russia as an international leader in cell therapy,” said Tereza Ustimova, CEO of ERCell.

About Medistem Inc.
Medistem Inc. is a biotechnology company developing technologies related to adult stem cell extraction, manipulation, and use for treating inflammatory and degenerative diseases. The company’s lead product, the endometrial regenerative cell (ERC), is a “universal donor” stem cell being developed for critical limb ischemia. A publication describing the support for use of ERC for this condition may be found at http://www.translational-medicine.com/content/pdf/1479-5876-6-45.pdf. ERC can be purchased for scientific use through Medistem’s collaborator, General Biotechnology http://www.gnrlbiotech.com/?page=catalog_endometrial_regenerative_cells.

Cautionary Statement
This press release does not constitute an offer to sell or a solicitation of an offer to buy any of our securities. This press release may contain certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking information. Factors which may cause actual results to differ from our forward-looking statements are discussed in our Form 10-K for the year ended December 31, 2007 as filed with the Securities and Exchange Commission.

Stem cells secrete factors that promote muscle growth after exercise

Stem cells that aid in healing disease and injury in skeletal muscle have been found inside muscles in greater numbers after exercise, according to a new animal study at the University of Illinois.

Just one exercise session increases the number of muscle-derived mesenchymal stem cells (mMSCs) in mice, according to Beckman Institute researcher Marni Boppart. Dr. Bopart is an assistant professor of kinesiology and community health at the University of Illinois.

mMSCs can differentiate (change) into many different cell types and are found throughout the body. For the first time, this study also showed that they also facilitate tissue healing indirectly.

Bopart said, “What we’ve been able to show in this paper and our current work is that mMSCs are not directly contributing to muscle growth, but do in fact secrete a variety of different factors that positively impact muscle growth.”

Bopart believes that these secreted factors, which specifically respond to mechanical strain are an important step toward treatments that can prevent muscle loss that occurs with aging.

This work was reported in the journal PlosOne.

Child’s Amazing Recovery from Cerebral Palsy Attributed to Cord Blood Stem Cells

Toddler diagnosed with cerebral palsy shows remarkable improvement


By Bob Considine
TODAYShow.com contributor

Dallas Hextell was already a miracle to parents Cynthia and Derak, after they spent three years trying to get pregnant.

But now he is looking like a medical miracle to the rest of the world.

The two-year-old son of the Sacramento, Calif., couple was diagnosed with cerebral palsy, but is now showing fewer signs of the disorder and marked improvement after an infusion of his own stem cells — made possible by the preservation of his own cord blood shortly before birth.

Derak Hextell now believes his son will be cured of the incurable malady.

“[Dallas’ doctors] said by the age of 7, there may be no signs of cerebral palsy at all,” Hextell told TODAY co-host Meredith Vieira while holding a curious Dallas on his lap. “So he’s on his way, as far as we’re concerned.”

For Cynthia Hextell, the changes in Dallas just five days after the intravenous infusion of his cord blood cells are not coincidental. “[He’s changed] almost in every way you can imagine, just from five days afterwards saying ‘mama’ and waving,” she said. “We just feel like right now he really connects with you. “It just seemed like a fog was over him before, like he just really wasn’t there. There was kind of, like a glaze in his eyes. Now, as you can see, you can’t get anything past him.”

A difficult start

The joy of Dallas’ birth in 2006 was met with gradual heartbreak as he was unable to feed from his mother. He was constantly crying and rarely opened his eyes. At five months, Dallas had trouble balancing himself and his head was often cocked to one side.
The Hextells switched pediatricians when Dallas was eight months old and was diagnosed with cerebral palsy — a group of nonprogressive disorders that affect a person’s ability to move and to maintain balance and posture.

Various studies show that the damage to the motor-control centers of the young, developing brain that causes CP occurs during pregnancy, although there are smaller percentages of the disorder occurring during childbirth and after birth through the age of 3.

“I think it’s important to remind people that cerebral palsy has to do with the motor part of the brain and usually kids don’t deteriorate,” said Dr. Nancy Snyderman, NBC News’ chief medical editor. “But they have significant motor problems, which explains why he wasn’t a good sucker when he was breast-feeding as a baby and all of this colicky stuff that sort of confused the diagnosis.”

There is no known cure for cerebral palsy, and the treatments to help manage its debilitating effects make it the second-most expensive developmental disability to manage over a person’s lifetime, behind mental disabilities.

At 18 months, Dallas had very limited motor skills. He could not crawl, clap or sit up and he communicated only through screaming brought on mostly by pain and frustration.

Life-changing decision

During her pregnancy, Cynthia Hextell had done thorough Web research on health issues relating to childbirth and came across a pop-up ad for Cord Blood Registry, the world’s largest family cord blood stem cell bank. The San Bruno, Calf.-based company has preserved cord blood stem cells for more than 200,000 newborns throughout the world.

Hextell said the cost of saving Dallas’ cord blood — about $2,000 and not covered by insurance — was off-putting. But she ultimately registered for CBR, thinking she would rather put up the money and not use it rather than have saved it and regretted it later.

(Cord Blood Registry spokesman David Zitlow said the procedure costs $2,000 for processing and $120 per year for storage.)

“We had a perfectly healthy pregnancy, but it did take us three years to get pregnant,” Cynthia Hextell told Vieira. “It was a good chance he was going to be our only child, so that was one thing that if we were going to do it, this was our only chance.

“Heart disease ran in [Derak Hextell’s] family. I was adopted, so I knew if we ever needed something, Dallas and I were the only ones [who could provide a genetic match]. So those were things [we considered], but nothing like I thought something was going to be wrong with my child. Literally, it took us until about two weeks before our due date to make the final decision because it is expensive.”

After Dallas was diagnosed, the Hextells traveled to Duke University, where doctors were using cord blood as part of a clinical trial to treat a small number of children who had cerebral palsy or brain damage. Mrs. Hextell called some of the parents of the children and all of them reported tangible improvement in their children following the transplant of stem cells, evidenced in better speech and motor skills.

So the Hextells agreed to infuse Dallas’ own stem cells back into his bloodstream last July, a procedure that took less than an hour.

Within five days, a different child emerged — laughing, clapping, waving and reacting.

“We think [the transfusion] has a real big part to do with it because it was such a drastic change within five days of the procedure taking place,” Derak Hextell said. “It had to be because he wasn’t reaching the milestones that he’s reaching now. He was falling further and further behind.”

“Before he went to Duke, we were trying to teach him to use a walker,” Cynthia Hextell said. “Now he walks with no assistance at all.”

Saving the cells

Although Dallas’ case was not part of a controlled case study, Snyderman said it should not be overlooked in the progressing studies of stem cell treatments.

“I think the thing that medicine has not done very well is we haven’t made a big enough deal about anecdotes,” she said. “This is not a controlled case study. It’s not a randomized clinical trial. But it is a child with a diagnosis who got a transfusion of stem cells and not only stopped the deterioration of his problems, [but] he’s doing better.
“So I take it very seriously. And I think it’s an extraordinary reminder that cord blood, that stuff that is thrown away with the placenta in the emergency room as sort of medical waste, can have extraordinary applications. We’re all offered it in the delivery room.”

Snyderman didn’t have to convince one person about the promise of those stem cells.

Said Cynthia Hextell: “They’re like gold.”

Umbilical cord stem cells may lead to new spinal cord injury and multiple sclerosis treatments

Researchers in Florida have accomplished converting umbilical cord stem cells into other cell types. According to University of Central Florida bioengineer James Hickman, it’s the first time that non-embryonic cells have accomplished this feat. His research group published this work in the January 18th issue of ACS Chemical Neuroscience.

Two major benefits of umbilical cord-derived stem cells are that they have not been shown to cause adverse immune system reactions and they pose no ethical issues since they come from a source that would be naturally discarded anyway.

Hedvika Davis, a post-doc researcher and lead author of the paper, had to search for the right chemical to coax the stem cells into becoming oligodendrocytes, which are cells that insulate nerves residing in the brain and spinal cord.

Other researchers had already shown that oligodendrocytes bind with a hormone called norepinephrine and Davis theorized that this could be the key. So she used norepinephrine and other growth factors to induce the cells to differentiate into oligodendrocytes. The only problem was that the cells were not sufficiently developed as they would be in the body.

So Davis devised a novel approach of approximating the body’s environment in the lab. By growing the cells on top of a slide, with another slide on top, Davis was able to simulate a 3-dimensional environment and grow mature oligodendrocytes.

Because oligodendrocytes produce myelin, researcher believe that this discovery might lead to treatments for multiple sclerosis, spinal cord injury and diabetic neuropathy.

Blood from young mice helps older mice with multiple sclerosis

A new mouse study has shown that blood from young mice helps old mice to heal damage caused by MS.

MS causes myelin, which insulates nerve cells electrically, to become damaged. Stem cells can produce myelin but they lose efficiency in older patients.

Researchers in the UK have found a way to reverse this age-related efficiency loss. By linking the bloodstreams of young mice to old mice with myelin damage, the older stem cells were reactivated and boosted myelin production.

White blood cells from the young mice called macrophages were found at myelin damage sites in the old mice. These cells engulf and destroy pathogens and debris, including destroyed myelin.

Amy Wagers, from Harvard University says, “We know this debris inhibits regeneration, so clearing it up is important.”

Stem Cell Therapy For Spinal Cord Injury and A Layman’s Guide To Adipose Stem Cell Therapy – Stem Cell Institute Seminar in Gilbert, AZ

The Treatment of Human Diseases with Adult Stem Cells

 

We are proud to present and discuss the latest in adult stem cell treatments for diseases. Join us for informational presentations by:

Jorge Paz Rodriguez, MDA Layman’s Guide to Adipose Stem Cell Therapy

Neil Riordan, PhDAdult Stem Cell Therapy for Spinal Cord Injury

Patients will be on hand to discuss their experiences.

 

April 21, 2011
Saturday
12:30 pm – 4:00 pm

Legato Hotel
San Tan Elegante Conference Center
Gilbert, AZ 85296

Register at www.cellmedicine.eventbrite.com

(800) 980-STEM (7836)

clinic@cellmedicine.com

The Key to Better Health May Lie in Adult Stem Cells

One of the oldest people in the world, Sarah Knauss (119 years old), might have had more than just “good genes.” “Adult stem cells – known for their healing and regenerative properties – might hold the key to a long and healthy life,” says Wayne Marasco, MD, PhD, of Dana-Farber at the recent International Vatican Conference on Adult Stem Cells in Vatican City, Italy.

“We have learned in the past 10 years that there are all kinds of stem cells that circulate in the blood – they aren’t just found in bone marrow,” said Marasco, of Dana-Farber’s Department of Cancer Immunology and AIDS. “There are dozens of studies that support the fact that this is a large and dynamic population of cells that might help us keep our bodies healthy for a longer period of time.”

Stem cells are assigned to specialized zones in the body and called into action when the body faces stress or even a minor injury. For example, when someone has a heart attack or stroke, an agent is released into the blood, recruiting stem cells and directing them to the damaged tissue.

In addition to their healing powers, stem cell levels are also an indicator of future health. Studies have shown that a person’s level of endothelial progenitor cells, stem cells that form the tissues that line blood vessels, can predict whether or not a patient who has a heart attack will die or need major hospitalization.

Since stem cell levels can be modified through diet, lifestyle changes, or drugs, monitoring stem cells could prevent certain health risks and delay disease from occurring.

“The bottom line is that stem cells may be a better indicator of health and aging than the regular annual blood test, which was developed 50 years ago,” Marasco says. “Now that we know more about adult stem cells, this should be part of a routine test.”

Stem cell therapy may not be too far off in the future. Marasco says that doctors will soon be able to check stem cell levels in a drop of blood, using a finger-prick test much like those used by diabetics. Studies are also beginning to show the benefits of an FDA-approved molecule that improves the healing powers of stem cells, and the NIH has launched a new program that may lead to discoveries of already approved drugs that can boost adult stem cells.

“We can age gracefully, but we can also keep the body revitalized,” Marasco said. “The whole purpose of monitoring is to replenish our stem cells so that we can get more healthy years out of them.”

Stem Cells May Reverse Age-Related Multiple Sclerosis Effects

Proof-of-principle study provides hope for stimulating remyelination

Scientists at Joslin Diabetes Center, Harvard University, and the University of Cambridge have found that the age-related impairment of the body’s ability to replace protective myelin sheaths, which normally surround nerve fibers and allow them to send signals properly, may be reversible, offering new hope that therapeutic strategies aimed at restoring efficient regeneration can be effective in the central nervous system throughout life.

In a proof-of-principle study published in the journal Cell Stem Cell, the researchers report that defects in the regeneration of the myelin sheaths surrounding nerves, which are lost in diseases such as multiple sclerosis may be at least partially corrected following exposure of an old animal to the circulatory system of a young animal. Myelin is a fatty substance that protects nerves and aids in the quick transmission of signals between nerve cells.

Using a surgical technique, the researchers introduced an experimental demyelinating injury in the spinal cord of an old mouse, creating small areas of myelin loss, and then exposed those areas to cells found the blood of a young mouse. By doing so, they found that the influx of certain immune cells, called macrophages, from the young mouse helped resident stem cells restore effective remyelination in the old mouse’s spinal cord. This “rejuvenating” effect of young immune cells was mediated in part by the greater efficiency of the young cells in clearing away myelin debris created by the demyelinating injury. Prior studies have shown that this debris impedes the regeneration of myelin.

“Aging impairs regenerative potential in the central nervous system,” says author Amy J. Wagers, PhD, an associate professor of stem cell and regenerative biology at Harvard University and Joslin, who co-led the study with Professor Robin Franklin, director of the MS Society’s Cambridge Centre for Myelin Repair at the University of Cambridge. “This impairment can be reversed, however, suggesting that the eventual development of cell-based or drug-based interventions that mimic the rejuvenation signals found in our study could be used therapeutically.”

This could be particularly useful, she adds, in treating MS, which typically spans many decades of life, and thus is likely to be influenced by age-dependent reductions in the ability of myelin to regenerate. In MS, the body’s own immune system attacks the myelin sheath and prevents nerve fibers in the brain from sending signals properly, which can cause mild symptoms such as limb numbness or more serious ones like losing the ability to walk or speak. As people with MS age, remyelination decreases significantly, eventually causing permanent loss of nerve fibers.

“For MS sufferers,” says Franklin, “this means that, in theory, regenerative therapies will work throughout the duration of the disease. Specifically, it means that remyelination therapies do not need to be based on stem cell transplantation since the stem cells already present in the brain and spinal cord can be made to regenerate myelin, regardless of a person’s age.”

Other Joslin co-authors of the study were Tata Nageswara Rao and Jennifer L. Shadrach.

About Joslin Diabetes Center
Joslin Diabetes Center, located in Boston, Massachusetts, is the world’s preeminent diabetes research and clinical care organization. Joslin is dedicated to ensuring that people with diabetes live long, healthy lives and offers real hope and progress toward diabetes prevention and a cure. Joslin is an independent, nonprofit institution affiliated with Harvard Medical School.

Adult Stem Cell Clinical Trials Showing Success

A Number of Clinical Trials Using Adult Stem Cells Are Showing Early Success

Dozens of adult stem cell treatments are moving through clinical trials and showing early success, raising hopes that some could reach the market within five years. ‘It will only take a few successes to really change the field,’ said Gil Van Bokkelen, chief executive of Athersys and chairman of the Alliance for Regenerative Medicine. ‘As you see things getting closer and closer to that tipping point, you’re going to see a frenzy of activity take place.’ Many of the trials focus on heart disease and inflammatory conditions, some of the biggest markets in medicine. The cells used are derived from adult tissue such as fat, or bone marrow, thereby circumventing the ethical concerns raised by the use of cells derived from embryos.

Data for the most part remains early, but as more results emerge, pharmaceutical companies are beginning to take note. ‘A lot of big companies are looking to place bets on some Phase II products once that data has been confirmed,’ said Paul Schmitt, managing partner at Novitas Capital. ‘Even now they’re attending all the medical meetings and talking to all the stem cell companies.’ Steven Martin, from Aspire Capital Partners LLC said they were willing to be patients as the benefits from treatment could be enormous. ‘My philosophy in the stem cell space is that it’s very difficult at this point to pick the winners and losers,’ he said. ‘We believe that over time there will be some very significant clinical progress, and valuations will improve, but we’re still a long way from an approved therapy.’

Aastrom Biosciences recently presented promising results from a mid-stage trial of its treatment for patients with critical limb ischemia, a disease in which blood flow to the extremities is restricted, at the American Heart Association’s annual meeting. A mid-stage trial from Australia’s Mesoblast Ltd showed its stem cell product reduced the rate of heart attacks and the need for artery clearing procedures by 78 per cent. ‘We’re actually developing products now,’ said Timothy Mayleben, chief executive of Aastrom, which is using cells derived from a patient’s own bone marrow to develop treatments for cardiovascular disease. ‘For the first time you are starting to see data being presented at major medical meetings.’ Pfizer Inc, Johnson & Johnson and Roche Holding AG are members of the Alliance for Regenerative Medicine, a nonprofit group that promotes awareness of the field. Pfizer has a regenerative medicine unit and a partnership with Athersys. But their projects are small as they want to wait to see data in hundreds of patients. The promise of stem cells, which have been used for 40 years in bone marrow transplants, lies in their ability to repair tissue, reduce inflammation, regulate the immune system, and respond to calls for help from multiple places inside the body. Stem cells are the body’s master cells – blank slates that renew themselves and mature into specific cell types in the heart, muscle and other organs.

Embryonic stem cells are uniquely capable of differentiating into every type of mature cell in the body, and were long viewed as the most promising for regenerating tissue. But harvesting stem cells from embryos requires the destruction of the embryo itself, a process opposed by conservative Christian groups. Moreover, their endless capacity to divide can lead to the formation of teratomas, or stem cell cancers. Recently, Geron Corp, the world’s leading embryonic stem cell company, said it could no longer fund its stem cell work and would focus on developing cancer drugs. It closed its trial for spinal cord injury. Unlike embryonic stem cells, adult stem cells have a more limited capacity to differentiate, but appear able to reduce inflammation and promote blood vessel formation. Furthermore, they can respond to damage in the body in a flexible and dynamic way, offering advantages over traditional drugs.
‘They seem to be preprogrammed to act some way in tissue repair, not to form an organ or a tissue,’ said Douglas Losordo, head of stem cell research at Baxter International Inc, which is developing cell therapies for heart disease. ‘The cells that we use are very effective at stimulating the formation of new blood vessels, but if I wanted to make a brain cell out of those cells they would not be very good at it.’ These are the type of stem cell treatments, delivered by infusion, injection or catheter, that are being developed today.
‘We wanted to create a product that everyone could receive and not have to match every donor to every recipient,’ said Robert Hariri, chief executive of Celgene’s Cellular Therapeutics unit.

Different types of stem cell are being used for different diseases. Cytori Therapeutics is developing a heart disease product derived from fat cells, for example, while Celgene is using placental cells for Crohn’s disease and rheumatoid arthritis therapies. Fetal cells are also being explored. Neuralstem Inc, for example, is developing treatments for neurological disorders from an aborted fetus. As cell therapies move further through clinical trials, companies will need more money, and funding is scarce.
Yet even if companies remain afloat long enough to bring a product through late-stage clinical trials, it is unclear what regulators like the Food and Drug Administration will require in order to approve them Some believe the regulatory hurdles for treatments derived from a patient’s own cells will be lower than those where the cells come from donors, since there is less risk of cell rejection. However, no clear pathway has yet been established. ‘We need a clear, consistent and rigorous regulatory framework,’ said Athersys’s Van Bokkelen. ‘The FDA is actually willing to provide lots of guidance and assistance to sponsors, if you just ask them.’